349 related articles for article (PubMed ID: 33182542)
21. AXL receptor as an emerging molecular target in colorectal cancer.
De Rosa L; Di Stasi R; Fusco V; D'Andrea LD
Drug Discov Today; 2024 Jun; 29(6):104005. PubMed ID: 38685399
[TBL] [Abstract][Full Text] [Related]
22. Targeting Axl and Mer kinases in cancer.
Verma A; Warner SL; Vankayalapati H; Bearss DJ; Sharma S
Mol Cancer Ther; 2011 Oct; 10(10):1763-73. PubMed ID: 21933973
[TBL] [Abstract][Full Text] [Related]
23. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
Antony J; Tan TZ; Kelly Z; Low J; Choolani M; Recchi C; Gabra H; Thiery JP; Huang RY
Sci Signal; 2016 Oct; 9(448):ra97. PubMed ID: 27703030
[TBL] [Abstract][Full Text] [Related]
24. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.
Holland SJ; Pan A; Franci C; Hu Y; Chang B; Li W; Duan M; Torneros A; Yu J; Heckrodt TJ; Zhang J; Ding P; Apatira A; Chua J; Brandt R; Pine P; Goff D; Singh R; Payan DG; Hitoshi Y
Cancer Res; 2010 Feb; 70(4):1544-54. PubMed ID: 20145120
[TBL] [Abstract][Full Text] [Related]
25. Axl is a prognostic marker in oral squamous cell carcinoma.
Lee CH; Yen CY; Liu SY; Chen CK; Chiang CF; Shiah SG; Chen PH; Shieh YS
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S500-8. PubMed ID: 21842265
[TBL] [Abstract][Full Text] [Related]
26. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.
Liu L; Greger J; Shi H; Liu Y; Greshock J; Annan R; Halsey W; Sathe GM; Martin AM; Gilmer TM
Cancer Res; 2009 Sep; 69(17):6871-8. PubMed ID: 19671800
[TBL] [Abstract][Full Text] [Related]
27. Targeting Gas6/TAM in cancer cells and tumor microenvironment.
Wu G; Ma Z; Cheng Y; Hu W; Deng C; Jiang S; Li T; Chen F; Yang Y
Mol Cancer; 2018 Jan; 17(1):20. PubMed ID: 29386018
[TBL] [Abstract][Full Text] [Related]
28. Endocytic trafficking of GAS6-AXL complexes is associated with sustained AKT activation.
Poświata A; Kozik K; Miączyńska M; Zdżalik-Bielecka D
Cell Mol Life Sci; 2022 May; 79(6):316. PubMed ID: 35622156
[TBL] [Abstract][Full Text] [Related]
29. Research Progress of Axl Inhibitors.
Sun ZG; Liu JH; Zhang JM; Qian Y
Curr Top Med Chem; 2019; 19(15):1338-1349. PubMed ID: 31218961
[TBL] [Abstract][Full Text] [Related]
30. AXL - a new player in resistance to HER2 blockade.
Adam-Artigues A; Arenas EJ; Arribas J; Prat A; Cejalvo JM
Cancer Treat Rev; 2023 Dec; 121():102639. PubMed ID: 37864955
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic aspects of the Axl/Gas6 molecular system.
Di Stasi R; De Rosa L; D'Andrea LD
Drug Discov Today; 2020 Dec; 25(12):2130-2148. PubMed ID: 33002607
[TBL] [Abstract][Full Text] [Related]
32. Suppression of the metastatic spread of breast cancer by DN10764 (AZD7762)-mediated inhibition of AXL signaling.
Park JS; Lee C; Kim HK; Kim D; Son JB; Ko E; Cho JH; Kim ND; Nan HY; Kim CY; Yoon S; Lee SH; Choi HG
Oncotarget; 2016 Dec; 7(50):83308-83318. PubMed ID: 27829217
[TBL] [Abstract][Full Text] [Related]
33. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.
Giles KM; Kalinowski FC; Candy PA; Epis MR; Zhang PM; Redfern AD; Stuart LM; Goodall GJ; Leedman PJ
Mol Cancer Ther; 2013 Nov; 12(11):2541-58. PubMed ID: 24026012
[TBL] [Abstract][Full Text] [Related]
34. The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer.
Uribe DJ; Mandell EK; Watson A; Martinez JD; Leighton JA; Ghosh S; Rothlin CV
PLoS One; 2017; 12(7):e0179979. PubMed ID: 28727830
[TBL] [Abstract][Full Text] [Related]
35. Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma.
Sadahiro H; Kang KD; Gibson JT; Minata M; Yu H; Shi J; Chhipa R; Chen Z; Lu S; Simoni Y; Furuta T; Sabit H; Zhang S; Bastola S; Yamaguchi S; Alsheikh H; Komarova S; Wang J; Kim SH; Hambardzumyan D; Lu X; Newell EW; DasGupta B; Nakada M; Lee LJ; Nabors B; Norian LA; Nakano I
Cancer Res; 2018 Jun; 78(11):3002-3013. PubMed ID: 29531161
[TBL] [Abstract][Full Text] [Related]
36. Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy.
Scaltriti M; Elkabets M; Baselga J
Clin Cancer Res; 2016 Mar; 22(6):1313-7. PubMed ID: 26763248
[TBL] [Abstract][Full Text] [Related]
37. AXL regulates mesothelioma proliferation and invasiveness.
Ou WB; Corson JM; Flynn DL; Lu WP; Wise SC; Bueno R; Sugarbaker DJ; Fletcher JA
Oncogene; 2011 Apr; 30(14):1643-52. PubMed ID: 21132014
[TBL] [Abstract][Full Text] [Related]
38. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
Torka R; Pénzes K; Gusenbauer S; Baumann C; Szabadkai I; Őrfi L; Kéri G; Ullrich A
Neoplasia; 2014 Apr; 16(4):301-18. PubMed ID: 24862757
[TBL] [Abstract][Full Text] [Related]
39. AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier.
Seike M; Kim CH; Zou F; Noro R; Chiba M; Ishikawa A; Κunugi S; Kubota K; Gemma A
Oncol Rep; 2017 Jun; 37(6):3261-3269. PubMed ID: 28440492
[TBL] [Abstract][Full Text] [Related]
40. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.
Meyer AS; Miller MA; Gertler FB; Lauffenburger DA
Sci Signal; 2013 Aug; 6(287):ra66. PubMed ID: 23921085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
